The global body contouring treatments market growth forecasted to transform from USD 1.46 billion in 2024 to USD 2.58 billion ...

The Rev. Mitchell Ikenna Johnson is resigning just seven days after he was sworn into office amid criticism over troubling ...

The U.S. macroeconomic environment remains favorable for investors. Current interest rates are in the range of 4.75-5.00% ...

The Rev. Mitchell Ikenna Johnson says he won’t resign, despite calls from 26 City Council members and other leaders. The ...

(Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, ...

Tech continues to rally as we await results from 5 of the Mag 7 …. the Nasdaq rose by 145 pts or 0.8% recording yet another record high for 2024… The Dow gave up 155 pts, the S&P gained 10 pts, the ...

Only three years after it was co-founded by Johnson & Johnson, Aliada Therapeutics Inc. is being acquired by Abbvie Inc. in a deal valued at $1.4 billion that gives the big pharma firm another shot at ...

October 28, 202410:12 PM UTCUpdated ago Oct 28 (Reuters) - U.S. drugmaker AbbVie (ABBV.N), opens new tab said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an ...

AbbVie is strengthening its neurology portfolio with a $1.4 billion acquisition of Aliada Therapeutics. The North Chicago-based drugmaker said in a statement this morning that Aliada has a blood ...

AbbVie aims to best those drugs through its acquisition of Aliada Therapeutics, a biotech whose technology enables large molecules such as antibodies to cross this protective barrier. AbbVie ...

AbbVie has made a big move in the Alzheimer’s space just a few months after it dropped its own internal candidate over the summer. On Monday, the pharma company announced a $1.4 billion acquisition of ...